Medication Development for Treatment of Alcoholism

描述（由申请人提供）：这项为期三年的P20中心资助提案通过将有经验的酒精研究人员与化学，蛋白质组学，基因传递和果蝇遗传学方面的新酒精领域专家聚集在一起，为酒精治疗的药物开发提供了新的范例。目标是开发必要的技术和合作，以确定药物开发的新靶点，并将我们对酒精靶点的了解转化为选择性配体。该中心由行政核心（Adron Harris， PI和中心主任），神经元特异性转录组学目标识别（Igor Ponomarev， PI），蛋白质组学目标识别（Dayne Mayfield， PI），高通量筛选配体选择（John Mihic， PI）和动物核心（Yuri Blednov， PI）组成，为项目提供小鼠和行为测试。此外，我们提出了两个试点项目（为期两年），以开发技术来测试新目标的生物学重要性。其中一个将提供将抑制性rna （RNAi）传递到大脑的工具（Maria Croyle， PI），另一个将开发携带靶基因突变的敲入果蝇（Nigel Atkinson， PI）。该中心设有内部和外部咨询委员会，由具有广泛专业知识的科学家提供专家指导。一个关键目标是为未来的P50应用提供必要的合作和基础设施，这将使新的研究人员和新技术集中在酒精依赖药物的开发上。

DESCRIPTION (provided by applicant): This three-year funding proposal for a P20 Center provides a new paradigm for medication development for the treatment of alcoholism by bringing experienced alcohol researchers together with experts in chemistry, proteomics, gene delivery and Drosophila genetics who are new to the alcohol field. The goal is to develop the technologies and collaborations necessary to define new targets for medication development and translate our knowledge of alcohol targets into selective ligands. The Center consists of an Administrative Core (Adron Harris, PI and Center Director), target identification by neuron-specific transcriptomics (Igor Ponomarev, PI), target identification by proteomics (Dayne Mayfield, PI), ligand selection by high throughput screening (John Mihic, PI), and an Animal Core (Yuri Blednov, PI) to provide mice and behavioral testing to the projects. In addition, we propose two Pilot Projects (two years in duration) to develop technology to test the biological importance of new targets. One will provide tools to deliver inhibitory RNAs (RNAi) to the brain (Maria Croyle, PI) and another will develop knock-in Drosophila carrying mutations in target genes (Nigel Atkinson, PI). The Center has both internal and external advisory boards, providing expert guidance from scientists with a wide range of expertise. A key aim is to provide the collaborations and infrastructure necessary for a future P50 application which will focus new researchers and new technologies on medication development for alcohol dependence.